Israel Englander’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-267,355
| Closed | -$711K | – | 6781 |
|
|
2024
Q1 | $711K | Sell |
267,355
-297,577
| -53% | -$737K | ﹤0.01% | 4574 |
|
|
2023
Q4 | $1.34M | Buy |
564,932
+7,674
| +1% | +$13.6K | ﹤0.01% | 3930 |
|
|
2023
Q3 | $780K | Sell |
557,258
-344,984
| -38% | -$829K | ﹤0.01% | 4354 |
|
|
2023
Q2 | $2.73M | Buy |
+902,242
| New | +$3.48M | ﹤0.01% | 3206 |
|
|
2022
Q4 | – | Sell |
-78,889
| Closed | -$943K | – | 7234 |
|
|
2022
Q3 | $943K | Buy |
+78,889
| New | +$1.03M | ﹤0.01% | 4395 |
|
|
2022
Q2 | – | Sell |
-13,683
| Closed | -$154K | – | 7679 |
|
|
2022
Q1 | $154K | Buy |
+13,683
| New | +$151K | ﹤0.01% | 5956 |
|
|
2021
Q4 | – | Sell |
-118,734
| Closed | -$2.73M | – | 7542 |
|
|
2021
Q3 | $2.73M | Buy |
+118,734
| New | +$2.58M | ﹤0.01% | 3553 |
|
|
2021
Q1 | – | Sell |
-89,796
| Closed | -$3.57M | – | 6617 |
|
|
2020
Q4 | $3.57M | Buy |
+89,796
| New | +$3.6M | ﹤0.01% | 2767 |
|
Israel Englander's KNTE Position: Q2 2024 in Review
Israel Englander sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 267,355 shares — an estimated $711K sold.
Israel Englander first reported a position in KNTE in Q4 2020 and held it in 8 quarters. The position peaked at $3.57M in Q4 2020. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.
- Israel Englander reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Israel Englander sold 267,355 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $711K.
- Israel Englander first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 8 quarters.
- Israel Englander's Kinnate Biopharma Inc. Common Stock position peaked at $3.57M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.
Based on Millennium Management's 13F filing for Q2 2024, filed 14 Aug 2024.